milvexian
janssen,bms
['axiomatic-ssp', 'janssen', 'bristol', '$bmy']
$bmy bristol myers squibb shares are trading lower after the company announced, in collaboration with janssen pharmaceuticals, the results from the phase 2 axiomatic-ssp dose-ranging study did not achieve the primary endpoint.
Just Started to use Twitter and I love it already. Been trading since 2015. only my thoughts not advise https://t.co/KqqkWXLZoO